A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with Flow cytometry and its application in the diagnostics of Alzheimer's disease.
A method for simultaneous quantification of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in human plasma is described. The method consists of a combination of immunoprecipitation using specific antibodies against the different forms of amyloid-beta, and immobilization of the immunocomplexes to magnetic beads. Addition of fluorescence-labelled antibodies which recognize the specific antibodies to the amyloid-beta subsets allows the peptide/associates detection in the sample by flow cytometry. The clinical assay performance was tested using blood samples from Alzheimer disease's patients and control donors. A sensitivity of 70% and a specificity of 81% was achieved.
Santos
Alexander Navarrete
AN
Department of Cardiothoracic Surgery, Martin-Luther University Halle Wittenberg, Ernst Grube Strasse 40, Halle, Germany. alexander.navarrete@medizin.uni-halle.de
Simm
Andreas
A
Holthoff
Vjera
V
Boehm
Gerald
G
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000097:blood*; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D047468:Immunoprecipitation / Q000379:methods; D008280:Magnetics; D008609:Mental Status Schedule; D008863:Microspheres; D010446:Peptide Fragments / Q000097:blood*; D011237:Predictive Value of Tests; D012016:Reference Values
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42)